TY - JOUR
T1 - Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer
AU - Passaro, Antonio
AU - Alesini, Daniele
AU - Pochesci, Alessia
AU - Cortesi, Enrico
PY - 2014
Y1 - 2014
N2 - Erlotinib and gefitinib are tyrosine kinase inhibitors (TKI) associated with the EGFR, which is involved in cell proliferation, growth, migration, invasion and survival, and has been found to be overexpressed in non-small-cell lung cancer. Erlotinib was the first target agent approved for the treatment of NSCLC in second-and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. In elderly patients, with a poor prognosis, and different co-morbidities, erlotinib and gefitinib could be considered as valid therapeutic options. This paper reviews the role of both drugs, in the management of elderly patients affected by advanced NSCLC based on an update analysis of randomised and non-randomised clinical trials.
AB - Erlotinib and gefitinib are tyrosine kinase inhibitors (TKI) associated with the EGFR, which is involved in cell proliferation, growth, migration, invasion and survival, and has been found to be overexpressed in non-small-cell lung cancer. Erlotinib was the first target agent approved for the treatment of NSCLC in second-and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. In elderly patients, with a poor prognosis, and different co-morbidities, erlotinib and gefitinib could be considered as valid therapeutic options. This paper reviews the role of both drugs, in the management of elderly patients affected by advanced NSCLC based on an update analysis of randomised and non-randomised clinical trials.
KW - Egfr
KW - Elderly
KW - Erlotinib
KW - Gefitinib
KW - Non-small-cell lung cancer
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84904466368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904466368&partnerID=8YFLogxK
U2 - 10.2174/187152061405140501101624
DO - 10.2174/187152061405140501101624
M3 - Article
C2 - 23140355
AN - SCOPUS:84904466368
VL - 14
SP - 646
EP - 650
JO - Anti-Cancer Agents in Medicinal Chemistry
JF - Anti-Cancer Agents in Medicinal Chemistry
SN - 1871-5206
IS - 5
ER -